Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells $278,891.49 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Scott Lish sold 23,183 shares of Alphatec stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $12.03, for a total value of $278,891.49. Following the completion of the sale, the chief operating officer now owns 844,494 shares of the company’s stock, valued at $10,159,262.82. This trade represents a 2.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Scott Lish also recently made the following trade(s):

• On Thursday, February 6th, Scott Lish sold 27,453 shares of Alphatec stock. The stock was sold at an average price of $11.49, for a total value of $315,434.97.

Alphatec Trading Up 3.4 %

Shares of Alphatec stock traded up $0.41 during trading on Friday, reaching $12.53. 3,473,121 shares of the company were exchanged, compared to its average volume of 1,786,753. The business has a 50-day moving average price of $10.63 and a 200-day moving average price of $8.37. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -9.79 and a beta of 1.43. Alphatec Holdings, Inc. has a twelve month low of $4.88 and a twelve month high of $14.88.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million during the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. Sell-side analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Alphatec

Several institutional investors and hedge funds have recently made changes to their positions in ATEC. PharVision Advisers LLC bought a new stake in Alphatec during the fourth quarter worth $201,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Alphatec by 11.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 224,643 shares of the medical technology company’s stock worth $2,062,000 after acquiring an additional 22,971 shares in the last quarter. Western Standard LLC purchased a new stake in shares of Alphatec in the fourth quarter worth approximately $6,668,000. Soviero Asset Management LP purchased a new stake in shares of Alphatec during the fourth quarter valued at approximately $918,000. Finally, Wexford Capital LP purchased a new stake in Alphatec in the fourth quarter worth $95,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on ATEC. Piper Sandler upped their target price on Alphatec from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Finally, Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.